Head-to-head · WeighScore
JRNYS vs ReadyRx
The verdict
JRNYS takes it — 71.7/100 to 67.6/100.
JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss program built around branded GLP-1 medications, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide, and liraglutide (Saxenda), paired…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | JRNYS | ReadyRx |
|---|---|---|
| WeighScore | 71.7/100 | 67.6/100 |
| Grade | C | C |
| Scorecard rank | #88 | #168 |
| Semaglutide | $89/mo (plus a separate fee, brand-name) | $179/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $255/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #88 · C
Strengths
- Branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda)
- Insured members may pay ~$25/mo for medication after deductible
- Includes 1-on-1 coaching at every membership tier
- Led by CMO Dr. Henry Legere with strong academic credentials
- Transparent membership pricing ($89-$169/mo)
Where it loses points
- Medication cost separate from membership; self-pay varies
- Best value requires commercial insurance coverage
- Compounded option not disclosed; brand-focused
- State availability not published
Graded #168 · C
Strengths
- LegitScript Certified — verifiable via the badge link in the footer
- Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
- Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide
Where it loses points
- Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
- Clinicians described as licensed and board-certified, but no names or credentials published
- 5,000+ member figure comes from a directory listing, not an independent audit
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.